307 related articles for article (PubMed ID: 20092407)
21. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.
Cherif H; Landgren O; Konradsen HB; Kalin M; Björkholm M
Vaccine; 2006 Jan; 24(1):75-81. PubMed ID: 16107293
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.
Leach AJ; Morris PS; Mackenzie G; McDonnell J; Balloch A; Carapetis J; Tang M
Vaccine; 2008 Jul; 26(31):3885-91. PubMed ID: 18562052
[TBL] [Abstract][Full Text] [Related]
24. Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?
Hey C; Rose MA; Kujumdshiev S; Gstoettner W; Schubert R; Zielen S
Laryngoscope; 2005 Sep; 115(9):1586-90. PubMed ID: 16148699
[TBL] [Abstract][Full Text] [Related]
25. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
26. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.
Givon-Lavi N; Greenberg D; Dagan R
Pediatr Infect Dis J; 2010 Aug; 29(8):756-62. PubMed ID: 20661103
[TBL] [Abstract][Full Text] [Related]
30. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
[TBL] [Abstract][Full Text] [Related]
31. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.
Remschmidt C; Harder T; Wichmann O; Bogdan C; Falkenhorst G
BMC Infect Dis; 2016 Nov; 16(1):711. PubMed ID: 27887596
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
Scott DA; Komjathy SF; Hu BT; Baker S; Supan LA; Monahan CA; Gruber W; Siber GR; Lockhart SP
Vaccine; 2007 Aug; 25(33):6164-6. PubMed ID: 17629361
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
[TBL] [Abstract][Full Text] [Related]
38. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
[TBL] [Abstract][Full Text] [Related]
39. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
[TBL] [Abstract][Full Text] [Related]
40. Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine.
Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
Vaccine; 2004 Jul; 22(21-22):2696-700. PubMed ID: 15246599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
